S-1/A: Sigyn Therapeutics Eyes Nasdaq Listing with Proposed Public Offering

Sigyn Therapeutics plans a firm commitment public offering of common stock and warrants to fund research and development, aiming for a Nasdaq listing.

Summary

• Sigyn Therapeutics, a development-stage company, is planning a public offering to raise capital for its blood purification technologies.
• The offering includes 703,125 Class A Units, each consisting of one share of common stock and one Series A Warrant to purchase one share of common stock.
• The assumed offer price is $12.80 per share of common stock, with a Series A Warrant exercise price of $14.08.
• The company is also offering pre-funded warrants to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%.
• Sigyn Therapeutics intends to use the net proceeds for research and development activities, clinical trials, regulatory review, working capital, and general corporate purposes.
• The company has applied to list its common stock on the Nasdaq Capital Market under the symbol SIGY, but there is no guarantee of approval.
• The offering is contingent upon Nasdaq approving the listing of the company's common stock.
• The company has granted the underwriters a 45-day option to purchase up to 105,469 additional shares of common stock and/or Series A Warrants to cover over-allotments.
• The company's lead product candidate, Sigyn Therapy, is being developed to treat life-threatening conditions such as endotoxemia and sepsis.
• The company plans to initiate first-in-human feasibility studies of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients with endotoxemia and concurrent inflammation.
• The company has drafted an Investigational Device Exemption (IDE) for submission to the U.S. Food and Drug Administration (FDA) to support the initiation of the proposed study.
• The company's therapeutic pipeline also includes ChemoPrep, ChemoPure, and ImmunePrep, designed to improve cancer drug delivery and efficacy.
• The company faces risks including market acceptance of its products, FDA testing requirements, the need for additional capital, and competition.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's technologies and the significant risks and challenges it faces as a development-stage company. The sentiment is neutral, reflecting the inherent uncertainties in the biotechnology industry.

Positives

• The company is developing innovative blood purification technologies to address unmet medical needs.
• The company's lead product, Sigyn Therapy, targets life-threatening conditions with no market-cleared drug agents.
• The company has a therapeutic pipeline that includes ChemoPrep, ChemoPure, and ImmunePrep, designed to improve cancer drug delivery and efficacy.
• The company is seeking a Nasdaq listing, which could increase its visibility and access to capital.
• The company has drafted an Investigational Device Exemption (IDE) for submission to the U.S. Food and Drug Administration (FDA) to support the initiation of the proposed study.

Negatives

• The company is a development-stage company with no approved products and no revenue.
• The company has incurred significant net losses since inception and does not anticipate generating revenue in the near future.
• The company's auditors have included a going concern qualification in their audit report for the fiscal year ended December 31, 2023.
• The company faces challenges in successfully completing FDA testing requirements and meeting increased regulatory requirements.
• There is no guarantee that the company's application to list its common stock on the Nasdaq Capital Market will be approved.
• There is no established trading market for the Series A Warrants, and the company does not expect a market to develop.

Risks

• Demand and market acceptance of the company's product offerings may be considerably less than what the company currently anticipates.
• The company may be unable to increase revenues in the manner in which it anticipates and generate profitability.
• The company may face challenges in successfully completing FDA testing requirements.
• The company may not be able to meet increased and changing regulatory requirements.
• The FDA may classify the company's lead product candidate to be a significant risk Class III device, which would require extensive pre-clinical and clinical studies to be conducted along with the submission of a Pre-Market Approval (PMA) application prior to market clearance consideration by FDA.
• The company will need to raise additional capital to fully commercialize its products.
• Some of the company's target products may face an uncertain regulatory environment.
• The company may be unable to expand operations and manage growth.
• The company may be unable to retain key members of its management and development teams and to recruit additional qualified personnel.
• The company faces competition from companies that have greater resources than it does and it may not be able to effectively compete against these companies.
• As stated in their audit opinion for the company's audited financials for the year ended December 31, 2022, the company's auditors believe that it may not be able to continue as a going concern.
• There is no established trading market for the Series A Warrants or pre-funded warrants being offered in this offering.
• The Series A Warrants are speculative.
• The Series A Warrants may not have any value and if an active, liquid trading market for the Series A Warrants does not develop, you may not be able to sell your warrants quickly or at or above the price you paid for them.

Future Outlook

The company believes that the net proceeds of this offering, together with its existing cash and cash equivalents, will enable it to fund its operating expenses and capital expenditure requirements for approximately the next two years from the date of this prospectus.

Industry Context

The industry to treat sepsis and other life-threatening inflammatory conditions is expected to become extremely competitive. The company faces competition from organizations that develop extracorporeal blood purification therapies.

Comparison to Industry Standards

• The company competes with Cytosorbents Corporation's CytoSorb, a cytokine adsorption technology market cleared in over 40 countries.
• The company competes with Toray Industries' Toraymyxn, a technology that removes circulating endotoxin and is licensed to Spectral Medical in North America.
• The company competes with Aethlon Medical's Hemopurifier, a device that removes pathogens from the bloodstream and has received FDA Emergency-Use Authorization (EUA) to treat Ebola virus.
• The company competes with Exthera Medical's Seraph-100 Microbind Affinity Filter, a device that removes bloodstream pathogens and is market cleared outside the U.S. for the removal of bloodstream pathogens.

Management Changes

Corporate Governance

Related Party Transactions

• The Company borrows funds from the Companys CEO for working capital purposes from time to time.
• The Company has recorded the principal balance due of $80,000 and $0 under Advance from Shareholder in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively.
• The Company received advances of $80,000 and $0 and had no repayments for the years ended December 31, 2023 and 2022.
• The advance from our CEO was not made pursuant to any loan agreements or promissory notes, are non-interest bearing and due on demand.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• The company's employees may benefit from the increased funding for research and development.
• Patients may benefit from the development of new blood purification technologies to treat life-threatening conditions.
• The company's suppliers and creditors may benefit from the increased financial stability of the company.

Next Steps

• Submit an Investigational Device Exemption (IDE) to the FDA to support the potential initiation of a human feasibility study in ESRD patients with endotoxemia and concurrent inflammation.
• Initiate first-in-human feasibility studies of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients with endotoxemia and concurrent inflammation.
• Apply to have the company's common stock listed on the Nasdaq Capital Market under the symbol SIGY.
• Continue the development and testing of the company's pipeline therapeutic candidates ChemoPrepTM, ChemoPureTM and ImmunePrepTM.

Key Dates

Keywords

Sigyn Therapeutics, public offering, Nasdaq, blood purification, Sigyn Therapy, warrants, endotoxemia, sepsis, ChemoPrep, ChemoPure, ImmunePrep, FDA, clinical trials, research and development